Richard Aspinall

Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study

Eleonora Scorletti, Lokpal Bhatia, Keith McCormick et al. · Hepatology · 2014 · 306 citations

Pathology, Epa Enrichment, Fatty Liver Disease +18

Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension

Dhiraj Tripathi, Adrian J. Stanley, Peter Hayes et al. · Gut · 2020 · 296 citations · Full text

Hypertension, Urology, Grade System +13

Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease

Eleonora Scorletti, Paul R. Afolabi, Elizabeth A. Miles et al. · Gastroenterology · 2020 · 208 citations · Full text

Dysbiosis, Microbiota, Gut Microbiology +7

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

Gideon M. Hirschfield, Mitchell L. Shiffman, Aliya Gulamhusein et al. · Hepatology · 2023 · 101 citations · Full text

Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials

Jason Grebely, Gregory J. Dore, Stefan Zeuzem et al. · Clinical Infectious Diseases · 2016 · 91 citations · Full text

Pharmacotherapy, Antiviral Drug, Viral Hepatitis +16